Please login to the form below

Not currently logged in
Email:
Password:

UK launch for gastrointestinal pharma firm

Belgian gastrointestinal pharmaceutical company Movetis has expanded its organisation with the launch of a new UK affiliate

Belgian gastrointestinal (GI) pharmaceutical company Movetis has expanded its organisation with the launch of a new UK affiliate.

Movetis (UK) will focus on the production of novel drugs to be used in the treatment of GI-related diseases where current options are limited.

The UK team includes eight representatives experienced in GI disorders. They will work with a range of products including Resolor (prucalopride), a treatment for chronic constipation in women in whom laxatives fail to provide adequate relief. Resolor was launched in the UK in March, 2010.

The company has said it plans further research involving prucalopride beyond its current indication.

Two products are currently in phase II development for Movetis, with a further two prioritised compounds in preclinical development. All products are aimed at addressing unmet needs in GI treatment.

David Trevor, general manager of Movetis (UK) said "The expansion of the business into the UK is an exciting time for Movetis. As a specialist GI pharmaceutical company we are able to focus our efforts and concentrate on ensuring new treatment options are made available for the management of gastrointestinal disease."

28th July 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

Numbers, navigation, and narratives: digital storytelling in medical communications
Science and storytelling aren’t often seen as compatible. One is based on cold, hard facts, while the other is synonymous with improvisation and theater. However, when done well, storytelling can...
Is this common data mistake killing your digital patient recruitment?
Without realising, you could be falling into the trap of using social data — insights into recent, relevant trends and topics — to inspire your content. Hold up. That sounds...
Dr Henry Skinner
The AMR Action Fund is combating antimicrobial resistance, but much more action is needed
By Henry Skinner, Chief Executive Officer of the AMR Action Fund...